What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide for obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Male or female * Age above or equal to 18 years at the time of signing informed consent * Body mass index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or b) BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease Exclusion Criteria: \- Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus
Study sites by state
Alabama
- Univ of Alabama Birmingham — Birmingham
California
- Velocity Clin Res Los Angeles — Los Angeles
- Velocity Clin Res Wstlke — Los Angeles
Colorado
- Univ of Colorado at Denver — Aurora
- OptumCare Clinical Trials LLC — Golden
Florida
- Northeast Research Institute — Fleming Island
- South Broward Research LLC — Miramar
- Clinical Neuroscience Solution — Orlando
- Florida Inst For Clin Res — Orlando
- Clinical Trial Res Assoc,Inc — Plantation
Georgia
- Hope Clin Res & Wellness — Conyers
Hawaii
- East West Med Res Inst — Honolulu
Illinois
- Great Lakes Clinical Trials — Chicago
- Endeavor Health — Skokie
- Evanston Premier Hlthcr Res — Skokie
Indiana
- Midwest Inst For Clin Res — Indianapolis
Michigan
- Northern Pines Hlth Ctr, PC — Buckley
Missouri
- StudyMetrix Research LLC — City of Saint Peters
New York
- Velocity Clinical Research Binghamton — Binghamton
- Comprehensive Weight Ctrl Prog — New York
North Carolina
- University of North Carolina — Chapel Hill
- University of North Carolina — Chapel Hill
- Medication Mgmnt, LLC_Grnsboro — Greensboro
- PharmQuest Life Sciences LLC — Greensboro
- Accellacare_NC — Raleigh
- Accellacare — Wilmington
Ohio
- New Venture Medical Research — Wadsworth
Oklahoma
- Lynn Institute of Norman — Norman
Pennsylvania
- The University of Penn Center — Philadelphia
Rhode Island
- Clinical Res Collaborative — Cumberland
South Carolina
- Medical Uni of SC Charleston — Charleston
- Coastal Carolina Res Ctr — North Charleston
- Hillcrest Clinical Research — Simpsonville
- Spartanburg Medical Research — Spartanburg
Tennessee
- Holston Medical Group_Bristol — Bristol
- Holston Medical Group — Kingsport
Texas
- Baylr Sctt White Rs Inst, Endo — Dallas
- Velocity Clinical Res-Dallas — Dallas
- UT Southwestern Med Cntr — Dallas
- DCOL Ctr for Clin Res — Longview
Virginia
- Washington Cntr Weight Mgmt — Arlington
- Health Res of Hampton Roads — Newport News
- Selma Medical Associates — Winchester
Washington
- Capital Clin Res Ctr,LLC — Olympia
- Rainier Clin Res Ctr Inc — Renton
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)